journal article·2023-02-10

Mixed Nanoscale Liposomes Co-Encapsulating Curcumin and Berberine Inhibit Activated Hepatic Stellate Cell-Induced Drug Resistance and Tumor Metastasis

Jingliang Wu, Cuiping Qi, Taotao Xu, Qingyun Zhang, Feifei Liu, Huifang Zhao, Jinping Dong, Xuemin Liu

ACS Applied Nano Materials· Volume 6· Issue 3
Publisher page

Abstract

The combination therapy based on nanoscale materials has been proven an effective approach for cancer treatment. In this study, berberine (BBR) and curcumin (CUR) were loaded into mixed liposomes (CUR-GL/BBR-HL). To simulate a tumor microenvironment (TME), the dual-cell research model (SMMC7721 + LX-2) and orthotopic tumor-bearing mice model were established for antiproliferation and antimetastasis evaluation. The results showed that the mixed liposomes exhibited strong cytotoxicity and antimigration effect against the dual-cell research model. Notably, CUR-GL/BBR-HL effectively inhibited the activation of hepatic stellate cells (HSCs), extracellular matrix deposition, and tumor angiogenesis in vivo, resulting in an enhanced anticancer effect. The anti-HCC mechanism revealed that CUR-GL/BBR-HL could inhibit drug resistance and the metastasis of tumor cells by downregulating the expression of P-gp and vimentin, respectively. Hence, the combined therapeutic strategy could effectively inhibit cancer growth, and CUR-GL/BBR-HL might be a potential formulation for anticancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Berberine and alkaloids research · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Nursing, Weifang University of Science and Technology, Weifang262700, P.R.China

School of Nursing, Weifang Medical University, Weifang261053, P.R.China

Department of Dermatology, Weifang People’s Hospital, Weifang261000, P.R.China

Department of Oncology, Weifang People’s Hospital, Weifang262700, P.R.China

School of Clinical Medicine, Weifang Medical University, Weifang261053, P.R.China

Funding

Weifang University of Science and Technology · National Natural Science Foundation of China

References (38)

Show source-provided references
1. 10.1016/j.jconrel.2016.12.04210.1016/j.jconrel.2016.12.042 ↗
2. 10.1007/s11684-019-0724-610.1007/s11684-019-0724-6 ↗
3. 10.1007/s00109-015-1283-110.1007/s00109-015-1283-1 ↗
4. 10.1007/s12079-019-00525-710.1007/s12079-019-00525-7 ↗
5. 10.3390/ijms1707103610.3390/ijms17071036 ↗
6. 10.1016/j.actbio.2019.09.03410.1016/j.actbio.2019.09.034 ↗
7. 10.1186/s13045-019-0739-010.1186/s13045-019-0739-0 ↗
8. 10.1016/j.canlet.2020.11.02510.1016/j.canlet.2020.11.025 ↗
9. 10.1016/j.ccell.2016.09.00410.1016/j.ccell.2016.09.004 ↗
10. 10.1139/cjpp-2018-055510.1139/cjpp-2018-0555 ↗
11. 10.1016/j.addr.2015.10.01310.1016/j.addr.2015.10.013 ↗
12. 10.1016/j.cell.2018.01.00910.1016/j.cell.2018.01.009 ↗
13. 10.1016/j.biomaterials.2017.09.02710.1016/j.biomaterials.2017.09.027 ↗
14. 10.1016/j.actbio.2018.06.01210.1016/j.actbio.2018.06.012 ↗
15. 10.1021/acsnano.8b0783010.1021/acsnano.8b07830 ↗
16. 10.1021/acsami.7b1824510.1021/acsami.7b18245 ↗
17. 10.1016/j.biomaterials.2018.01.04310.1016/j.biomaterials.2018.01.043 ↗
18. 10.1021/nn502861t10.1021/nn502861t ↗
19. 10.1021/acssynbio.9b0034910.1021/acssynbio.9b00349 ↗
20. 10.1021/acsami.7b1449610.1021/acsami.7b14496 ↗
21. 10.1021/acsnano.9b0416610.1021/acsnano.9b04166 ↗
22. 10.1016/j.biomaterials.2021.12100310.1016/j.biomaterials.2021.121003 ↗
23. 10.2147/IJN.S18897110.2147/IJN.S188971 ↗
24. 10.1021/acsami.2c1044610.1021/acsami.2c10446 ↗
25. 10.1016/j.ijpharm.2022.12171410.1016/j.ijpharm.2022.121714 ↗
26. 10.1016/j.lfs.2018.03.04610.1016/j.lfs.2018.03.046 ↗
27. 10.1016/j.actbio.2018.02.00410.1016/j.actbio.2018.02.004 ↗
28. 10.3892/ol.2017.754110.3892/ol.2017.7541 ↗
29. 10.1038/s41419-020-2613-y10.1038/s41419-020-2613-y ↗
30. 10.1002/jcp.2954510.1002/jcp.29545 ↗
31. 10.1371/journal.pone.018002310.1371/journal.pone.0180023 ↗
32. 10.1016/j.ijpharm.2020.11999310.1016/j.ijpharm.2020.119993 ↗
33. 10.1038/nrd.2016.19310.1038/nrd.2016.193 ↗
34. 10.1016/j.canlet.2014.10.02110.1016/j.canlet.2014.10.021 ↗
35. 10.1002/hep.3019310.1002/hep.30193 ↗
36. 10.1002/hep.3066810.1002/hep.30668 ↗
37. 10.1002/smll.20130358810.1002/smll.201303588 ↗
38. 10.1016/j.ccell.2019.08.00710.1016/j.ccell.2019.08.007 ↗